Insights
Gauging the Impact of High-Impact Drugs in Workers’ Comp
Rivian Certified Collision Network Summit 2024
As the first collision industry information provider to sign a data licensing agreement with Rivian, Mitchell is proud to be a Platinum Sponsor of the 2024 Certified Collision Network Summit.
Plugged-In: EV Collision Insights Q2 2024
3 MIN READ
Claims frequency for repairable, collision-damaged battery electric vehicles (BEVs) rose to 2.5% in the U.S. and 3.94% in Canada in Q2 2024—a year-over-year increase of 45% and 39% respectively. According to the Alliance for Automotive Innovation, EVs represented 9.3% of new U.S. light-duty vehicle sales in Q1 2024, down from 10.2% in Q4 2023. Similarly, in Canada BEV sales fell to 9.2% last quarter, down from 10% in Q4 2023.
An Overlooked Essential: Hospital Discharge Planning in Workers’ Compensation
In a recent article, Jim Begg, Vice President of National Accounts for Apricus, highlights the critical role of effective discharge planning in helping patients recover swiftly and safely.
Bridging the Gap for New Adjusters with Innovative Tools
Streamline your claims process and support your team with our cutting-edge solutions.
SEMA 2024
The SEMA Show is the premier destination for manufacturers and buyers looking to discover thousands of the latest innovations in the automotive aftermarket industry.
New Trends in Opioids and Pain Management
Despite decreases in utilization and cost per claim, opioids remain the No. 1 drug class in Enlyte’s 2024 Drug Trends Report. However, due to concerns with safety and overutilization, increased focus on usage guidelines as well as alternatives to pain management are gaining momentum — including those whose active ingredients drive from things you might not imagine, like pufferfish, cacti and chili peppers. Enlyte’s Nikki Wilson explores this and more in our Part 3 drug trends analysis.